Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neoadjuvant therapy for cervical cancer.

H Kuehnle1, H G Meerpohl, W Eiermann

  • 1Department of Gynecology and Obstetrics, Hannover University, Germany.

Seminars in Oncology
|February 1, 1992
PubMed
Summary

This study explored carboplatin and ifosfamide chemotherapy for advanced cervical cancer. While showing effectiveness, significant hematologic toxicity limits its use in adjuvant settings.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Statistical controversies in clinical research: statistical significance-too much of a good thing ….

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.

Annals of oncology : official journal of the European Society for Medical Oncology·2014

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology
  • Clinical Pharmacology

Background:

  • Cervical cancer prognosis has stagnated over recent decades.
  • Adjuvant chemotherapy research for early stages prompted this study in advanced stages.
  • Limited treatment options exist for advanced cervical cancer.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of a carboplatin plus ifosfamide regimen in advanced cervical cancer patients.
  • To assess treatment response, including remission rates.
  • To identify and quantify adverse events associated with the chemotherapy regimen.

Main Methods:

  • Pilot study involving 34 untreated patients with advanced cervical cancer.
  • Treatment regimen: carboplatin (300 mg/m2) plus ifosfamide (5 g/m2) on day 1, repeated every 4 weeks for remission or no change.
  • Subsequent treatment with surgery or radiotherapy based on feasibility.

Main Results:

  • 32 patients and 88 chemotherapy courses were evaluable.
  • 19 patients achieved remission, including 3 complete remissions.
  • Most common toxicities: grade four leukopenia (28%), thrombocytopenia (13%), and alopecia (60%).

Conclusions:

  • The carboplatin/ifosfamide regimen demonstrates comparable efficacy to other platin-based treatments for squamous cell carcinoma of the cervix uteri.
  • Significant hematologic toxicity, particularly myelosuppression, restricts its recommendation for adjuvant therapy.
  • Further research may be needed to optimize this regimen or explore alternative treatments for advanced cervical cancer.

Related Experiment Videos